Biochemistry
-
Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
This article has 7 authors:Reviewed by ScreenIT
-
Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis
This article has 34 authors:Reviewed by ScreenIT
-
Genotypic and antigenic study of SARS-CoV-2 from an Indian isolate
This article has 14 authors:Reviewed by ScreenIT
-
Specific viral RNA drives the SARS CoV-2 nucleocapsid to phase separate
This article has 16 authors:Reviewed by ScreenIT
-
SARS‐CoV‐2 nucleocapsid protein phase‐separates with RNA and with human hnRNPs
This article has 6 authors:Reviewed by ScreenIT
-
A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection
This article has 19 authors:Reviewed by ScreenIT
-
The Utility of Native MS for Understanding the Mechanism of Action of Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the SARS-CoV-2 Interaction with Its Host Cell Receptor
This article has 3 authors:Reviewed by ScreenIT
-
Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells
This article has 17 authors:Reviewed by ScreenIT
-
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
This article has 36 authors:Reviewed by ScreenIT
-
Closing coronavirus spike glycoproteins by structure-guided design
This article has 4 authors:Reviewed by ScreenIT